ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1390

Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis

Cécile Gaujoux-Viala1, Mohamed Belkacemi2, Alain Cantagrel3, Bruno Fautrel4 and Bernard Combe5, 1Rheumatology, Nîmes University Hospital and EA2415 Montpellier University, Nîmes, France, 2EA2415 Montpellier University, Montpellier, France, 3Rheumatology, Toulouse University Hospital and Toulouse University, Toulouse, France, 4UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, 5Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Disease Activity, outcome measures and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 6, 2017

Title: Rheumatoid Arthritis – Clinical Aspects Poster II: Pathophysiology, Autoantibodies, and Disease Activity Measures

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: DAS28 is often used as a treatment decision tool in patients with rheumatoid arthritis (RA) in the daily clinic. Although different versions of DAS28 have previously been validated, and although disease activity thresholds are the same, it is not clear whether DAS28-ESR and DAS28-CRP can be used interchangeably in individual patients.

Objectives: The aims of our study were to examine the agreement between these two DAS28 versions in individual early RA patients in the daily clinic and to idenditify factors related to the discrepancies between disease activity levels according to these 2
scores.

Methods: Baseline and 6 months data from 677 patients with early RA (ACR EULAR 2010) were extracted from the French cohort of early arthritis ESPOIR (at least 2 swollen joints for less than 6 months, DMARD naïve) and were used to calculate DAS28-ESR and DAS28-CRP. Disease activity levels according to the DAS thresholds and EULAR responses were assessed.

Intraclass correlation coefficient [ICC] and weighted kappa (k) were calculated. The Bland-Altman method was used to examine the bias between the DAS scores and the 95% limits of agreement (LoA).

Multivariate logistic regression was used to determine the patient and RA features independently associated with discrepancies between disease activity levels according to DAS28-ESR and DAS28-CRP.

Results: The mean value of DAS28-CRP (5.04±1.16 at M0 and 3.38±1.33 at M6) was smaller than that of mean DAS28-ESR (5.33±1.24 at M0 and 3.51±1.42 at M6).

Agreement between the scores was excellent: ICC=0.93 at M0 and M6. Agreement between disease activity levels according to the 2 scores was good: k=0.70 at M0 and 0.75 at M6. Agreement between EULAR responses at M6 according to the 2 scores was good: k=0.78. At M0, the bias of DAS28-CRP was -0.28 (LoA -1.16, 0.59) and -0.14 (LoA -1.17,0.89) at M6.

There were discrepancies between disease activity levels according to the 2 scores in 122 (18.6%) patients at M0 with clear difference in moderate (88 patients for DAS28-CRP vs 29 for DAS28-ESR) and high disease activity (18 patients for DAS28-CRP vs 80 for DAS28-ESR), and in 171 (28.1%) patients at M6 with clear difference in remission (42 patients for DAS28-CRP vs 29 for DAS28-ESR) and high disease activity (9 patients for DAS28-CRP vs 32 for DAS28-ESR).

At M0, presence of erosion (OR 95%CI=1.76 [1.07-2.90]), better mental component of the SF36 (OR 95%CI=2.14 [1.38-3.31]), fewer tender joint counts (TJC) and better physical component of the SF36 (PCS) (with significant interaction between TJC and PCS) were associated with discrepancies between disease activity levels according to the 2 scores. At M6, only being male (OR 95%CI=1.62 [1.09-2.41]) was associated with discrepancies.

Conclusion: DAS28-CRP significantly underestimated disease activity compared to DAS28-ESR. Agreement was high between the 2 scores, good for disease activity levels and EULAR responses. In the individual patient, however, the two scores may differ considerably. The scores should not be used interchangeably in the daily clinic without caution.


Disclosure: C. Gaujoux-Viala, None; M. Belkacemi, None; A. Cantagrel, None; B. Fautrel, None; B. Combe, None.

To cite this abstract in AMA style:

Gaujoux-Viala C, Belkacemi M, Cantagrel A, Fautrel B, Combe B. Agreement between the DAS28-ESR and the DAS28-CRP and Factors Related to the Discrepancies between Disease Activity Levels According to These 2 Scores in Patients with Early Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/agreement-between-the-das28-esr-and-the-das28-crp-and-factors-related-to-the-discrepancies-between-disease-activity-levels-according-to-these-2-scores-in-patients-with-early-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/agreement-between-the-das28-esr-and-the-das28-crp-and-factors-related-to-the-discrepancies-between-disease-activity-levels-according-to-these-2-scores-in-patients-with-early-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology